Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Celularity Inc. (CELU)

1.57   -0.09 (-5.42%) 11-25 13:00
Open: 1.76 Pre. Close: 1.66
High: 1.76 Low: 1.53
Volume: 248,506 Market Cap: 228(M)

Technical analysis

as of: 2022-11-25 1:55:52 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.38     One year: 2.87
Support: Support1: 1.35    Support2: 1.12
Resistance: Resistance1: 2.03    Resistance2: 2.46
Pivot: 1.86
Moving Average: MA(5): 1.56     MA(20): 1.97
MA(100): 2.64     MA(250): 5.07
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 17.9     %D(3): 12.7
RSI: RSI(14): 35.5
52-week: High: 13.18  Low: 1.35
Average Vol(K): 3-Month: 669 (K)  10-Days: 542 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CELU ] has closed above bottom band by 20.5%. Bollinger Bands are 21.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.73 - 1.75 1.75 - 1.76
Low: 1.37 - 1.38 1.38 - 1.39
Close: 1.64 - 1.66 1.66 - 1.68

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Headline News

Tue, 22 Nov 2022
Down 35.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU) - Nasdaq

Mon, 21 Nov 2022
Healthcare Stocks Moving Monday: IMGO, CDIO, NMTC, SHC, GMVD, TCBP, IVVD, CELU - InvestorsObserver

Mon, 21 Nov 2022
Celularity Inc. (NASDAQ:CELU) to Post FY2022 Earnings of ($0.61) Per Share, HC Wainwright Forecasts - MarketBeat

Fri, 11 Nov 2022
Health Care Sector Update for 11/11/2022: CELU, TAK, TMO, XLV, IBB - Nasdaq

Thu, 10 Nov 2022
Celularity, Inc. (CELU) Q3 Earnings Beat Estimates - Zacks Investment Research

Thu, 10 Nov 2022
Celularity GAAP EPS of $0.03 (NASDAQ:CELU) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 145 (M)
Shares Float 55 (M)
% Held by Insiders 65 (%)
% Held by Institutions 24.3 (%)
Shares Short 2,270 (K)
Shares Short P.Month 3,010 (K)

Stock Financials

EPS 0.4
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.13
Profit Margin (%) -76.4
Operating Margin (%) -760.7
Return on Assets (ttm) -20.1
Return on Equity (ttm) -11
Qtrly Rev. Growth -61.1
Gross Profit (p.s.) 0.08
Sales Per Share 0.12
EBITDA (p.s.) -0.92
Qtrly Earnings Growth -92.5
Operating Cash Flow -140 (M)
Levered Free Cash Flow -71 (M)

Stock Valuations

PE Ratio 3.82
PEG Ratio 0
Price to Book value 1.37
Price to Sales 12.17
Price to Cash Flow -1.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.